Lilly’s Omvoh follows induction with maintenance in ulcerative colitis

The Tip Desk · September 23, 2026 · 1 min read

The approved IL-23 antibody starts with infusions and moves to injections, with maintenance evidence drawn from patients who first responded.

Mirikizumab, the antibody marketed as Omvoh, blocks IL-23 signaling. The FDA approved it for adult ulcerative colitis in October 2023. It supplies an established biologic comparator for newer mechanisms, with an intravenous induction phase followed by subcutaneous maintenance.

The linked LUCENT studies distinguish a 12-week induction trial from a 40-week maintenance trial entered by induction responders. FDA's summary found greater remission rates than placebo in both stages. The maintenance population had already demonstrated a response, so its remission percentage cannot be compared directly with an unselected induction population.

For competition, that treatment sequence matters alongside mechanism. Initial infusions and later injections have different delivery requirements from an oral regimen. Evidence of benefit does not remove infection or other safety considerations, and the full prescribing information remains the source for current warnings and eligibility. This profile does not infer a superior benefit-risk balance against another IL-23 therapy or a TL1A candidate.

The development history remains open after approval, but this baseline does not establish a particular next ulcerative-colitis readout. New indication evidence should be recorded separately rather than allowed to overwrite the UC story. Corporate balances and earnings are not a disclosed mirikizumab development allocation.

Lilly reported $8.950 billion of cash and equivalents at June 30. Short-term borrowing and current debt totaled $7.050 billion, with $47.858 billion of long-term debt. First-half operating cash generation was $16.023 billion and net income $14.491 billion. Its investment portfolio includes venture and private investments, which should not all be added to cash as immediately available liquidity. The corporate cash-generation base supports a broad development and manufacturing program; the accounts do not allocate these balances to any individual compound discussed here.